Claims for Patent: 7,794,732

Summary for Patent: 7,794,732

Title:	Anthrax compositions and methods of use and production
Abstract:	Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of an antigenic epitope associated with anthrax toxin proteins optionally combined with a pharmaceutically acceptable carrier. The preferred antigenic epitopes correspond to immunogenic regions of protective antigen, lethal factor or edema factor, either individually or in combination. In addition, methods and compositions containing antibodies for reducing the effects of anthrax toxins are described. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an immune response or treat the anthrax infection.
Inventor(s):	James; Judith A. (Edmond, OK), Farris; Darise (Edmond, OK), Crowe; Sherry (Midwest City, OK)
Assignee:	Oklahoma Medical Research Foundation (Oklahoma City, OK)
Application Number:	11/748,268
Patent Claims:	1. A composition comprising an isolated immunogenic peptide consisting of 40 or less amino acids and comprising SEQ ID NO: 170. 2. The composition of claim 1, wherein the peptide is coupled to a carrier. 3. The composition of claim 2, wherein the carrier is a protective antigen protein. 4. The composition of claim 1, further comprising a second immunogenic peptide derived from Bacillus anthracis. 5. A composition comprising an immunogenic fusion protein of two or more immunogenic peptides, wherein at least one peptide of the two or more immunogenic peptides consists of 40 or less amino acids and comprises SEQ ID NO: 170. 6. The composition of claim 1, wherein the peptide consists of 20 amino acids or less. 7. A method of inducing an immune response comprising administering to an animal or a human an effective amount of the composition of claim 1. 8. A method of producing an antibody comprising administering to an animal or a human an effective amount of the composition of claim 1. 9. The method of claim 8, wherein the antibody is a monoclonal or polyclonal antibody. 10. A method of producing an antibody comprising administering to an animal or a human an effective amount of the composition of claim 5. 11. A method for detecting an antibody infection in an animal or a human comprising combining a sample from the animal or the human with an immunoreactive peptide, wherein the peptide consists of SEQ ID NO:170, and detecting a complex formed between the antibody in the sample and the immunoreactive peptide, wherein detection of a complex indicates anthrax infection in the animal. 12. A method for detecting specific protective immunity to anthrax infection in an animal or a human comprising combining a sample from the animal with an immunoreactive peptide, wherein the peptide has 40 or less amino acids and comprises SEQ ID NO:170 has, and detecting a complex formed between an antibody in the sample and the immunoreactive peptide, wherein detection of a predetermined amount of complex indicates specific protective immunity to anthrax infection in the animal. 13. The composition of claim 5, wherein the at least one peptide consists of 20 amino acids or less. 14. The composition of claim 1, wherein the peptide consists of between 12 and 18 amino acids. 15. The composition of claim 5, wherein the at least one peptide consists of between 12 and 18 amino acids.

Details for Patent 7,794,732

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2026-05-12